PharmacyCodes



Diphenoxylate-Atropine en es it fr

Diphenoxylate-Atropine Brand names, Diphenoxylate-Atropine Analogs

Diphenoxylate-Atropine Brand Names Mixture

  • Lomotil (Atropine Sulfate + Diphenoxylate Hcl)

Diphenoxylate-Atropine Chemical_Formula

C30H32N2O2

Diphenoxylate-Atropine RX_link

http://www.rxlist.com/cgi/generic3/diphenoxylate.htm

Diphenoxylate-Atropine fda sheet

Diphenoxylate-Atropine msds (material safety sheet)

Diphenoxylate-Atropine MSDS

Diphenoxylate-Atropine Synthesis Reference

Janssen, U.S. pat. 2,898,340 (1959)

Diphenoxylate-Atropine Molecular Weight

452.587 g/mol

Diphenoxylate-Atropine Melting Point

221 oC

Diphenoxylate-Atropine H2O Solubility

0.8 mg/ml

Diphenoxylate-Atropine State

Solid

Diphenoxylate-Atropine LogP

7.385

Diphenoxylate-Atropine Dosage Forms

Oral solution; Tablet

Diphenoxylate-Atropine Indication

For as adjunctive therapy in the management of diarrhea

Diphenoxylate-Atropine Pharmacology

Diphenoxylate, an antidiarrheal, is effective as adjunctive therapy in the management of diarrhea. Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood.

Diphenoxylate-Atropine Absorption

90%

Diphenoxylate-Atropine side effects and Toxicity

Coma, dry skin and mucous membranes, enlarged pupils of the eyes, extremely high body temperature, flushing, involuntary eyeball movement, lower than normal muscle tone, pinpoint pupils, rapid heartbeat, restlessness, sluggishness, suppressed breathing

Diphenoxylate-Atropine Patient Information

INFORM THE PATIENT (PARENT OR GUARDIAN) NOT TO EXCEED THE RECOMMENDED DOSAGE AND TO KEEP DIPHEN-OXYLATE HCL AND ATROPINE SULFATE OUT OF THE REACH OF CHILDREN AND IN A CHILD-RESISTANT CONTAINER, INFORM THE PATIENT OF THE CONSEQUENCES OF OVERDOSAGE, INCLUDING SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH.

Diphenoxylate HCl and atropine sulfate may produce drowsiness or dizziness. The patient should be cautioned regarding activities requiring mental alertness, such as driving or operati ng dangerous machinery. Potentiation of the action of alcohol, barbiturates and tranquilizers with concomitant use of diphenoxylate HCl and atropine sulfate should be explained to the patient. The physician should also provide the patient with other information in this labeling, as appropriate.

Diphenoxylate-Atropine Organisms Affected

Humans and other mammals